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Abstract
Missing data are a common issue in cost‐effectiveness analysis (CEA) alongside
randomised trials and are often addressed assuming the data are ‘missing at
random’. However, this assumption is often questionable, and sensitivity anal-
yses are required to assess the implications of departures from missing at ran-
dom. Reference‐based multiple imputation provides an attractive approach for
conducting such sensitivity analyses, because missing data assumptions are
framed in an intuitive way by making reference to other trial arms. For exam-
ple, a plausible not at random mechanism in a placebo‐controlled trial would
be to assume that participants in the experimental arm who dropped out stop
taking their treatment and have similar outcomes to those in the placebo arm.
Drawing on the increasing use of this approach in other areas, this paper aims
to extend and illustrate the reference‐based multiple imputation approach in
CEA. It introduces the principles of reference‐based imputation and proposes
an extension to the CEA context. The method is illustrated in the CEA of the
CoBalT trial evaluating cognitive behavioural therapy for treatment‐resistant
depression. Stata code is provided. We find that reference‐based multiple impu-
tation provides a relevant and accessible framework for assessing the robust-
ness of CEA conclusions to different missing data assumptions.
KEYWORDS
controlled imputation, cost‐effectiveness analysis, missing data, missing not at random, multiple
imputation, randomised trial, reference‐based, sensitivity analysis
1 | INTRODUCTION
Cost‐effectiveness analysis (CEA) of randomised trials provides an important source of information for decision making
but is often limited by incomplete data collection. For example, participants may withdraw before the end of the study
or fail to complete a questionnaire. This is particularly common in longitudinal studies, where data are collected at
multiple follow‐up points, as is often the case in CEA. There has been substantial progress in methods for handling
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missing data in CEA particularly those that allow valid inferences under the assumption that data are missing at ran-
dom (MAR; Briggs, Clark, Wolstenholme, & Clarke, 2003; Burton, Billingham, & Bryan, 2007; Faria, Gomes, Epstein,
& White, 2014; Lin, 2003; Manca & Palmer, 2005; Oostenbrink & Al, 2005; Willan, Lin, & Manca, 2005). In recent years,
there has been an increase in the uptake of methods such as multiple imputation (Gabrio, Mason, & Baio, 2017;
Leurent, Gomes, & Carpenter, 2018; Noble, Hollingworth, & Tilling, 2012). The MAR assumption often provides a desir-
able starting point for missing data analyses as it implies that any differences between individuals with missing and
complete information can be explained by differences in the observed data. However, this assumption may not always
hold, as the missingness could depend on unobserved values, that is, data are missing not at random (MNAR; Little &
Rubin, 2002). For example, participants in poorer health may be less likely to complete health‐related quality of life
(QoL) questionnaires (e.g., EQ‐5D; EuroQol Group, 1990), conditional on their observed characteristics (Faria et al.,
2014; Leurent et al., 2018).
Because the true missing data mechanism is unknown, methodological guidelines recommend conducting sensitivity
analyses to departures from the MAR assumption, considering alternative, plausible MNAR mechanisms (Burzykowski
et al., 2010; Committee for Medicinal Products for Human Use [CHMP], 2010; Faria et al., 2014; Little et al., 2012).
However, these sensitivity analyses are not routinely conducted (Bell, Fiero, Horton, & Hsu, 2014; Gabrio et al., 2017;
Leurent, Gomes, & Carpenter, 2018), perhaps due to the lack of accessible methods or because of the challenges of for-
mulating relevant missing data assumptions beyond MAR. One approach that is receiving increasing attention in clin-
ical trials is reference‐based multiple imputation (Carpenter, Roger, & Kenward, 2013; Keene, Roger, Hartley, &
Kenward, 2014; Kenward, 2015; Little & Yau, 1996). This approach recognises that individuals with missing data could
differ from those who complete the study, and—reflecting this—the data are imputed using a different distribution. For
example, in a placebo‐controlled drug trial, participants in the experimental arm who dropout may stop taking their
treatment and be expected to have similar outcomes to those in the placebo arm. A key advantage of this approach over
other methods that have been proposed (Gabrio, Daniels, & Baio, 2018; Gabrio, Mason, & Baio, 2019; Leurent, Gomes,
Faria, et al., 2018; Mason, Gomes, Grieve, & Carpenter, 2018) is that the departure from MAR is captured in a qualita-
tive way, making the formulation of the problem more intuitive and accessible to a broader audience, including clini-
cians and decision makers.
Drawing on recent work (Carpenter et al., 2013), this paper extends and illustrates the reference‐based multiple
imputation approach to address MNAR data in trial‐based CEA. In particular, we focus on adapting the approach to
jointly model costs and effectiveness and allow for different patterns of missingness on cost and effectiveness endpoints
over time.
This paper is organised as follows: Section 2 introduces the CoBalT trial, which is used as a motivating example to
illustrate the methods. Section 3 introduces the reference‐based multiple imputation approach, its extension to the
CEA framework, and its implementation in Stata (StataCorp, 2017). Section 4 illustrates the methods applied to the
CoBalT trial. The paper finishes with a discussion of the proposed methods.
2 | CASE STUDY
2.1 | Overview of the CoBalT trial
CoBalT was a two‐arm individually randomised controlled trial of cognitive behavioural therapy (CBT) as an adjunct
to pharmacotherapy for treatment‐resistant depression (Wiles et al., 2014, 2013). Patients with treatment‐resistant
depression were recruited from U.K. primary care practices between 2008 and 2010 and randomised to either
usual care for depression (including pharmacotherapy) or to CBT in addition to usual care. CBT consisted of 12
to 18 sessions delivered by a trained therapist at the general practice or a nearby location and followed standard
CBT manuals (Thomas et al., 2012). The trial's primary outcome was clinical response, defined as a 50% reduction
in depressive symptoms (Beck Depression Inventory‐II; Beck, Steer, & Brown, 1996) at 6 months compared with
baseline.
2.2 | Cost‐effectiveness analysis
A 1‐year CEA was conducted alongside the trial to assess the cost‐effectiveness of CBT in addition to usual care and has
been reported in detail elsewhere (Hollinghurst et al., 2010; Wiles et al., 2014). For the purpose of this article, we follow
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broadly the CEA methods described in Hollinghurst et al. (2010) with some simplifications made to allow a clearer
focus on the relevant methodology (e.g., focussing only on unadjusted cost‐utility analysis and costs from the National
Health Service and Personal Social Service perspective). Briefly, health‐related QoL was measured by the EQ‐5D‐3L
(EuroQol Group, 1990) at baseline, 6, and 12 months and converted into utility scores using a standard set of U.K. val-
uations (Dolan, 1997). Quality‐adjusted life‐years (QALYs) were derived by the “area under the curve” approach, com-
bining both time and utility scores (Drummond, Sculpher, Claxton, Stoddart, & Torrance, 2015). Costs were measured
from the National Health Service and Personal Social Service perspective over 12 months. Primary care use was
derived from the general practice records at the end of the trial, and additional health and social service use were mea-
sured by patient questionnaires at 6 and 12 months. Costs were not collected at baseline. For the purposes of this arti-
cle, we focused on imputing the total cost variable. Missing QoL data and total costs were imputed under different
assumptions using the referenced‐based multiple imputation approach described in Section 3. Participants' baseline
QoL, age, sex, and Beck Depression Inventory‐II were used as covariates in the imputation model, and a set of 100
imputations were performed. The imputed QALYs were then derived by the area under the curve approach based
on the imputed QoL at baseline, 6, and 12 months. The resulting multiply‐imputed datasets were analysed using
Rubin's rules (Rubin, 1987). Mean differences between arms in QALYs and costs (and 95% confidence intervals) were
estimated using unadjusted linear regression and divided to obtain the incremental cost‐effectiveness ratio (ICER) of
CBT compared with usual care. The probability of CBT being cost‐effective at different willingness to pay thresholds
(and the resulting cost‐effectiveness acceptability curve; Fenwick, O'Brien, & Briggs, 2004) were derived using unad-
justed “seemingly unrelated regressions” (Willan, Briggs, & Hoch, 2004) for QALYs and for costs. All analyses were
performed in Stata version 15 (StataCorp, 2017).
2.3 | Missing data patterns and descriptive results
The trial enrolled 469 participants, and 101 (21.5%) had some cost or QoL data missing. Table 1 shows the frequency of
each missing data pattern for the cost and QoL variables. The cost endpoint had slightly more missing data than the
QoL endpoint, and the missing data were mostly monotone (when QoL was unobserved at 6 months, QoL at 12 months
and total costs tended to be missing as well), but there were also some participants with interim‐missing data (QoL miss-
ing at 6 months but observed at 12 months). The majority of participants were in the “completers” pattern (78.5%), and
each of the missing data pattern had a small number of participants (from 0 to 23 per arm), with the most common
being not having any follow‐up data (9%). There was no important difference between arms, with 77.4% of participants
providing complete data in the usual care arm and 79.5% in the CBT arm. Missing data were mostly due to participants
withdrawing from the study or being lost to follow‐up during the trial and were more common in men and younger
participants (Wiles et al., 2014).
Table 2 reports the observed mean and standard deviation for the cost and QoL variables. The mean QoL over time
is also shown by missing data pattern in Figure 1. In the participants with complete QALY data, the QoL tended to
increase over time, with a greater improvement in the CBT arm than the usual care arm, particularly between baseline
and 6 months. Participants with missing data tended to have a lower QoL at baseline.
The primary CEA (Hollinghurst et al., 2010) was conducted using multiple imputation, assuming missing data
were MAR. However, due to the nature of the illness, it was argued that those with poorer outcomes could have been
TABLE 1 Missing data patterns of CoBalT quality of life and cost variables
Missing data pattern Usual care (N = 235) CBT (N = 234) Total (N = 469)
QoL baseline QoL 6 months QoL 12 months Total cost n % n % n %
✓ ✓ ✓ ✓ 182 77.4 186 79.5 368 78.5
✓ ✓ ✓ 13 5.5 6 2.6 19 4.1
✓ ✓ ✓ 0 0.0 2 0.9 2 0.4
✓ ✓ 18 7.7 14 6.0 32 6.8
✓ ✓ 3 1.3 3 1.3 6 1.3
✓ 19 8.1 23 9.8 42 9.0
Note. Ticks indicate observed data; crosses indicate missing data.
Abbreviations: CBT, cognitive behavioural therapy; QoL, health‐related quality of life measured by the EQ‐5D‐3L.
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more likely to dropout of the trial (i.e., data may be MNAR). To ensure that the study provides sound evidence, it is
therefore important to assess the extent to which the cost‐effectiveness inferences are robust to departures from the
primary MAR assumption. Reference‐based imputation provides a particularly appealing framework to conduct these
sensitivity analyses under varying missing data assumptions, as we will see in the following sections.
3 | REFERENCE ‐BASED MULTIPLE IMPUTATION
This section starts by introducing the basic principles of the reference‐based multiple imputation approach drawing on
recent work (Carpenter et al., 2013). We then provide some technical details and describe how the approach can be
extended for the CEA setting and implemented in standard statistical software.
3.1 | Overview
Reference‐based multiple imputation is part of the reference‐based (or “controlled” or “placebo‐based”) approaches
to handling missing data (Ayele, Lipkovich, Molenberghs, & Mallinckrodt, 2014; Carpenter et al., 2013; Keene
et al., 2014; Kenward, 2015; Little & Yau, 1996; Lu, 2014; Tang, 2018), which belong to a broader class of “pattern
TABLE 2 Summary statistics of CoBalT quality of life and cost variables
Variable
Usual care (N = 235) CBT (N = 234)
n M SD n M SD
QoL baseline 235a 0.502 0.311 234 0.547 0.315
QoL 6 months 213 0.542 0.329 206 0.662 0.303
QoL 12 months 198 0.555 0.358 197 0.637 0.338
QALYs 195 0.542 0.292 192 0.635 0.279
Total cost (£) 182 799 725 188 1,803 1,115
Abbreviations: CBT, cognitive behavioural therapy; M, mean; QALYs, quality‐adjusted life‐years; QoL, health‐related quality of life measured by EQ‐5D‐3L; SD,
standard deviation.
aOne missing baseline QoL was mean‐imputed.
FIGURE 1 CoBalT mean quality of life scores, by treatment arm and missing data pattern. The number of participants in each pattern is
indicated next to the last observation. Linear change is assumed between time points. CBT, cognitive behavioural therapy
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mixture models,” modelling MNAR data by allowing for a different data distribution by pattern of missingness (Lit-
tle, 1993; Ratitch, O'Kelly, & Tosiello, 2013). Reference‐based multiple imputation can be seen as an extension of
ad hoc single imputation MNAR methods, such as assuming “missing = still smoking” commonly used in
smoking cessation trials (West, Hajek, Stead, & Stapleton, 2005) but appropriately capturing random variations
and imputation uncertainty in a multiple imputation framework. Instead of a single imputation, an appropriate dis-
tribution is used to draw multiple plausible values. This distribution can come from any “reference” group, but a
typical choice in randomised trials would be to use the control arm information. For example, in a placebo‐
controlled trial, we may wish to use the distribution from the placebo arm to impute outcomes of active arm indi-
viduals who dropped out (assuming these have stopped taking their treatment). Multiple imputation provides a
convenient framework to implement this approach, because it naturally builds on the MAR elements (Carpenter
et al., 2013). Once a multivariate model has been fitted assuming MAR, the different elements of the model can
be used as “building blocks” to construct the desired distribution under MNAR. We describe this more formally
in the next section.
3.2 | Generic algorithm
Consider a randomised controlled trial, where an outcome (say QoL) is measured at multiple time points. Let i = 1, … ,
N index the N participants randomised in the trial, and Ti indicate the randomisation arm of participant i. Let j index
the time points, j = 0, … , J, with j = 0 the baseline measurement. Yij denotes the value of the outcome for participant i at
time j. Let YOi and YMi denote the vectors of observed and missing variables for participant i. For now, let us also assume
that all the missing data are due to dropout, so that for a participant i, data are all observed until time point Di ∈ {0, … ,
J}, and missing thereafter. So YOi = (Yi0, … , YiDi)
T, and YMi = (YiDi+ 1, … , YiJ)
T.
To impute the missing values, we need to define a distribution for the missing data YMi, given the treatment arm and
observed data, that is (YMi|YOi, Di, Ti). Under MAR, this distribution is independent of Di and is (YMi|YOi, Ti). Under
MNAR assumptions, however, it depends on Di, and we need to define the distribution according to some plausible
assumption. A practical option is to make statements about the unobserved data by reference to other groups of partic-
ipants in the trial (typically participants in different treatment arms).
Reference‐based multiple imputation involves the following steps (Carpenter et al., 2013; Cro, Morris, Kenward, &
Carpenter, 2016):
1. For each treatment arm separately, fit a multivariate normal (MVN) model for Yij using the observed data (assum-
ing MAR).
2. Draw a mean vector and a covariance matrix from the posterior distribution of the MVN model parameters.
3. For each participant with missing data, use the draw from Step 2 to form the joint distribution of YOi and YMi. Dif-
ferent assumptions can be used to construct this joint distribution (see Section 3.3).
4. For each participant, use the joint distribution to construct the conditional distribution of YMi given YOi and draw
random values from that conditional distribution to impute the missing data.
5. Repeat Steps 2–4 m times to construct m imputed datasets.
The analysis can then be conducted as with standard multiply‐imputed datasets. That is, the parameters of interest
and their variances are estimated by fitting the model of interest to each dataset and combined using Rubin's rules
(Rubin, 1987). Guidance for the analysis of multiply‐imputed cost‐effectiveness data is provided elsewhere (Briggs
et al., 2003; Burton et al., 2007; Faria et al., 2014; Manca & Palmer, 2005).
3.3 | Constructing the joint distribution
Several options to construct the joint distribution of the observed and unobserved data have been proposed, each
reflecting a different MNAR mechanism (Carpenter et al., 2013). The appropriate choice will be context‐specific, but
here, we describe some options that may be of particular relevance to trial‐based CEA. Each of these options is illus-
trated in Figure 2.
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Randomised arm MAR. The distributions of the missing and observed values, conditionally on the observed vari-
ables, are assumed to be the same. The joint distribution follows an MVN with mean and covariance corresponding
to the participant's randomised arm estimates. It corresponds to the default assumption with the standard multiple
imputation approach. This is the natural choice when missingness is assumed independent of the outcome, or to
estimate a “de jure” (per protocol) estimand, censoring after any protocol deviation.
Jump to reference (J2R). After dropout, the participant's conditional outcomes are assumed to “jump” to those of the
reference group (typically the control arm). The joint distribution is an MVN model with mean parameters from the
randomised arm until Di and from the reference group afterward. The covariance matrix corresponds to the parameters
from the randomised arm until Di and to the reference group for the conditional components of the post‐dropout
variables, given the pre‐dropout measurements. It corresponds to assuming that, after dropping out, participants from
the active arm have the same outcomes as the reference group individuals. This is a plausible choice when the treat-
ment effect is lost after the individual leaves the study.
Copy increments in reference (CIR). After dropout, the participant's conditional outcomes mimic (parallel) the
gradient from the reference group. The joint distribution mean parameters follow those from the randomised arm until
dropout and the increment in mean from the reference group thereafter. The covariance matrix is formed as under J2R.
This may be plausible when participants are expected to maintain the treatment benefits accrued until dropout, then
follow (parallel) the outcome trajectory from the reference group after that.
Last mean carried forward (LMCF). After dropout, the participant's conditional outcomes remain stable, around the
mean at that last time point (from their treatment arm). The joint distribution is anMVNwithmean parameters from the
randomised arm until dropout, and the mean parameter from their randomised arm at time Di for all the following time
points. The covariance parameters follow those of the randomised arm. This is an appropriate choice when the outcomes
are likely to remain stable, on average, after dropout. Note that this is distinct from the ad hoc “last observation carried
forward” approach (Molenberghs et al., 2004), as values are drawn from a well‐defined posterior distribution.
Baseline mean carried forward (BMCF). After dropout, the participant's conditional outcomes are assumed to
“jump” back to the baseline mean level. The joint distribution is an MVN with mean parameters from the randomised
arm until dropout, and the mean parameter from their randomised arm at baseline for the following time points. The
covariance parameters follow those of the randomised arm. This assumption may be plausible when participants are
FIGURE 2 Illustration of reference‐based imputation options. Black squares are observed values for a participant in the active arm
dropping out after the third time point. Hollow diamonds represent the average imputed values for that participant, and the curly
brackets represent the imputation uncertainty around that average. The reference group (for J2R and CIR) is the control arm. Note that for
clarity, the participant is assumed to follow closely the mean of its arm before dropout. The imputed values will actually depend on the
observed data, and, for example, a participant with higher values before dropout will tend to have higher imputed values. BMCF, baseline
mean carried forward; CIR, copy increments in reference; J2R, jump to reference; LMCF, last mean carried forward; MAR, missing at
random [Colour figure can be viewed at wileyonlinelibrary.com]
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anticipated to lose treatment benefits and return to their baseline values. Although this option was not considered in
Carpenter et al. (2013), it seemed relevant in our motivating example.
Note that for J2R and CIR, we need to specify a reference group (typically the control arm). For a participant already
in the reference group, the distribution will be the same as under MAR.
3.4 | Extension to cost‐effectiveness data
In this section, we build on the original framework described above to handle key features commonly encountered in CEA.
3.4.1 | Handling cost and effectiveness endpoints
The MVN framework in which the algorithm is implemented can be extended naturally to accommodate additional
endpoints. Although in the original model the size of the Yij vector was defined by the number of repeated measures,
it can be extended to a vector of size J* = Je + Jc, where Je and Jc capture the number of repeated measures of effective-
ness and costs, respectively. This results in an MVN model defined, for each treatment arm, by a mean vector of size J*,
and a variance–covariance matrix of size J* × J*. The joint distribution options described above in Section 3.3 can be
logically extended for two distinct endpoints, which do not necessarily have to follow the same follow‐up measurements
schedule (Je ≠ Jc) or missing data pattern. For example, with J2R, the distribution of the unobserved cost and effective-
ness variables, conditional on the observed variables, can be set to follow the conditional distributions for the corre-
sponding variables from the reference arm. Or with LMCF, it is simply the mean for the corresponding endpoint
(cost or effectiveness) that is carried forward to the following time points.
3.4.2 | Allowing for differential missing data assumptions between endpoints
An important feature of cost‐effectiveness data is that the mechanism that gives rise to missing costs may differ from
that of missing effectiveness data. For example, the data may come from different sources (e.g., case report forms versus
patient‐reported questionnaires) or be collected at different time points. We may want to assume that only one of the
endpoints is MNAR and that the other may be MAR. To allow for this, for each participant i, YMi can be split in two vec-
tors: YMARi, consisting of the MAR‐missing variables, and YMNARi, of the MNAR‐missing variables. The conditional dis-
tribution of YMNARi given YOi and YMARi can then be defined following the options described above. The mean parameters
are straightforward to derive, following the principles described in Section 3.3, with the mean parameters from the MAR‐
missing variables corresponding to those from the randomised arm. For MAR, LMCF, and BMCF, the covariance matrix
will be that of the randomised arm. For J2R and CIR, the covariance matrix requires some further derivation, and the
technical details are reported in Data S1. Once the joint distribution has been defined, the remaining steps of the algo-
rithm (see Section 3.2) can be followed, drawing values for (YMARi, YMNARi) conditionally on YOi for each participant.
3.4.3 | Interim‐missing data
So far, it was assumed that missing data were monotone within each endpoint (cost or effectiveness), so that all data
were missing after a given point in time. It is however common for trial‐based CEA to have interim‐missing data (an
endpoint measure is missing at a particular time point but observed at a subsequent follow‐up point). We have
extended the reference‐based framework to accommodate this. If the interim and dropout missing data mechanisms
are the same, the joint distribution can be naturally defined. For example, with J2R, we can assume that for each
individual, the missing (interim or dropout) variables follow the distribution from the reference group conditionally
on the observed data. Similarly, for LMCF, the mean carried forward can be drawn from the last observation before
the missing time point. However, the reasons for the interim‐missing data may differ from those of the dropout, and
it will sometime seem sensible to assume that only dropout missing data are MNAR (and that the interim‐missing
are MAR). In this case, the joint distribution can be built following the approach described in Section 3.4.2, with
the interim‐missing data added to the vector of YMARi variables. The MNAR endpoints would then follow the spec-
ified distribution, conditionally on the observed and the interim‐missing variables.
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3.5 | Implementation in Stata
Drawing on the mimix Stata command (Cro et al., 2016), we developed CEmimix, a Stata do‐file to implement reference‐
based multiple imputation for cost‐effectiveness data. The code is reported in Data S2, and available online (Leurent,
Gomes, Cro, Wiles, & Carpenter, 2019). Instructions for using CEmimix are provided in Data S3. In brief, the user needs
to specify the list of effectiveness and cost variables, the treatment arm variable, any additional imputation covariates,
and the choice of imputation methods for the effectiveness and cost endpoints. The program then follows the algorithm
described in Section 3.2 and returns the corresponding multiply‐imputed datasets which can be analysed using the mi
estimate command in Stata. Optionally, it allows the user to specify different imputation methods for the interim‐
missing data and to restrict the multiple imputation to a subset of participants. Further technical details are provided
in the code file (Data S2) and in Cro et al. (2016).
4 | RESULTS
In this section, we illustrate the reference‐based multiple imputation approach for assessing the sensitivity of the
CoBalT cost‐effectiveness results to different missing data assumptions.
4.1 | MAR analysis
For the base‐case analysis, we assumed that missingness was independent of the unobserved outcome values given the
observed data (MAR). It is not possible to test whether this assumption holds based on the observed data, but it often
constitutes a sensible starting point. Results are reported in Table 3 and Figure 3. Under MAR, participants in the
CBT arm had significantly higher QALYs and costs than the usual care arm. This resulted in an ICER of £11,260 per
QALY and a 90.8% probability of CBT being cost‐effective at a willingness to pay threshold of £20,000 per QALY.
4.2 | MNAR sensitivity analyses
We then conducted sensitivity analysis under different MNAR assumptions. First, it was assumed that participants
dropping out from the CBT arm stopped engaging with the intervention and that their QoL and costs followed (“jumped
TABLE 3 CoBalT reference‐based imputation results under MAR and J2R assumptions
Missing data
assumption
Usual care (N = 235) CBT (N = 234) Difference (N = 469)
M [95% CI] M [95% CI] M [95% CI]
MAR assumption
QoL 6 months 0.537 [0.494, 0.581] 0.653 [0.611, 0.694] 0.115 [0.055, 0.175]
QoL 12 months 0.547 [0.498, 0.595] 0.625 [0.579, 0.671] 0.079 [0.012, 0.145]
QALYs 0.531 [0.492, 0.569] 0.619 [0.582, 0.657] 0.088 [0.035, 0.142]
Total cost (£) 803 [694, 912] 1,798 [1,641, 1,956] 996 [802, 1,190]
ICER (£/QALY) 11,260
Probability cost‐effectivea 90.8%
J2R assumptionb
QoL 6 months 0.537 [0.494, 0.581] 0.640 [0.597, 0.683] 0.103 [0.042, 0.164]
QoL 12 months 0.547 [0.498, 0.595] 0.614 [0.566, 0.661] 0.067 [0.000, 0.134]
QALYs 0.531 [0.492, 0.569] 0.610 [0.572, 0.649] 0.079 [0.025, 0.134]
Total cost (£) 803 [694, 912] 1,615 [1,464, 1,767] 813 [630, 996]
ICER (£/QALY) 10,244
Probability cost‐effectivea 90.8%
Note. Based on m = 100 imputations.
Abbreviations: CBT, cognitive behavioural therapy; ICER, incremental cost‐effectiveness ratio; J2R, jump to reference; M, mean; MAR, missing at random;
QALYs, quality‐adjusted life‐years; QoL, quality of life.
aAt £20,000/QALY.
bAssuming QoL and costs for dropout participants in CBT arm jump to usual care values. Interim‐missing QoL assumed to be MAR.
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to”) that of the control group from that point onwards (J2R). Interim‐missing data were assumed to be MAR. We can see
in Table 3 how this assumption affected the mean QoL and cost estimates at the different time points. The QoL esti-
mates in the CBT arm reduced towards the values of the usual care arm, resulting in a smaller difference in overall
QALYs. Similarly, for the cost, the CBT arm costs were lower than under MAR, resulting in a smaller difference
between arms. Overall, under this assumption, the ICER of CBT was slightly lower than under MAR (£10,244 per
QALY), but the probability of being cost‐effective at £20,000 per QALY was unaffected (90.8%; Table 3). We can see
on the cost‐effectiveness acceptability curve (Figure 3) that MAR and J2R results were relatively similar across different
willingness to pay thresholds, with a probability of CBT being cost‐effective above 90% for any willingness to pay thresh-
old above £20,000 per QALY.
We then explored the impact of further missing data assumptions, for which results are summarised in Table 4. We
first conducted the same sensitivity analysis but assumed that interim‐missing QoL data also “jumped to reference”
(J2R‐interim). This had little impact on the results (Table 4). We then assumed that only QoL were J2R and that costs
were MAR (J2R‐MAR). This was to represent a conservative scenario (for CBT cost‐effectiveness), assuming that
participants dropping out from the CBT arm “jumped to” the QoL from the usual care group but that costs would still
be similar to completers in the CBT arm. Finally, we conducted a more extreme scenario where we assumed that QoL of
dropout participants went back to baseline values (BMCF). Note that this is likely conservative in terms of within‐arm
QALYs but not necessarily in terms of difference between arms. Although the exact estimates varied slightly under
these different missing data assumptions, none significantly affected the CEA conclusions, with an ICER ranging from
£10,244 to £12,552 per QALY and a probability of being cost‐effective between 84.4% and 90.8% at £20,000 per QALY
(Table 4 and Figure 3). Overall, these results suggest that for any willingness to pay above £20,000 per QALY, CBT is
likely to provide good value for money, and the trial CEA conclusions appear robust to various missing data
mechanisms.
5 | DISCUSSION
This study proposes a sensitivity analysis framework for addressing MNAR cost‐effectiveness data using the reference‐
based multiple imputation approach. Drawing on recent work proposed to address missing clinical outcomes in longi-
tudinal trials (Carpenter et al., 2013), our paper extends reference‐based multiple imputation to jointly handle missing
FIGURE 3 Cost‐effectiveness acceptability curve under different missing data assumptions. J2R‐interim curve not shown, similar to J2R
curve. Based on N = 469 participants and m = 100 imputations. Based on seemingly unrelated regression of the imputed datasets,
alternative approaches such as nonparametric bootstrapping could have been used (Faria et al., 2014). BMCF, baseline mean carried forward;
CBT, cognitive behavioural therapy; J2R, jump to reference; MAR, missing at random; QALYs, quality‐adjusted life‐years [Colour figure can
be viewed at wileyonlinelibrary.com]
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cost and effectiveness endpoints and allows for features commonly seen in CEA, such as interim‐missing data. We illus-
trated the approach in the CoBalT trial, evaluating the cost‐effectiveness of CBT as an adjunct to pharmacotherapy for
primary care patients with treatment‐resistant depression (Wiles et al., 2014). We formulated contextually plausible
departures from the MAR assumption and found that the trial cost‐effectiveness conclusions were robust to varied
missing data assumptions. The software code was also provided, with instructions, to facilitate the implementation of
the methods.
The development of sensitivity analysis strategies for addressing potential departures from the MAR assumption in
trial‐based CEA is an active area of research (Faria et al., 2014; Gabrio et al., 2018; Leurent, Gomes, Faria, et al.,
2018; Mason et al., 2018). One of the key strengths of reference‐based imputation compared with other sensitivity anal-
ysis approaches is the intuitive formulation of the missing data assumptions. This matters because the main challenge
when conducting missing data sensitivity analysis is to formulate assumptions that are contextually relevant and acces-
sible to a broad audience. Although similar claims have been made using other pattern mixture models (Faria et al.,
2014; Leurent, Gomes, Faria, et al., 2018; Mason et al., 2018), these typically formulate departures from MAR in terms
of quantitative differences between observed and missing data, which are less straightforward to interpret. Another
strength of this approach is that it can be conveniently implemented after MAR multiple imputation, which is increas-
ingly used to address missing data in trial‐based CEA (Gabrio et al., 2017; Leurent, Gomes, & Carpenter, 2018).
Although the potential of reference‐based imputation is more obvious in longitudinal trials, it is also relevant with sin-
gle follow‐up trials and provides a convenient way to conduct “worst‐case”‐type scenarios while appropriately preserv-
ing the variance and imputation uncertainty.
A potential limitation of the proposed approach is that its current implementation relies on an MVN model, whereas
QALYs and costs are likely to be nonnormally distributed. MVN multiple imputation is, however, recognised as robust
to nonnormal data, as long as the estimators of interest are normally distributed (Bernaards, Belin, & Schafer, 2007; Lee
& Carlin, 2017; Schafer, 1997; von Hippel, 2013). This is expected to be the case for most trial‐based CEA but could be
an issue in small trials (say less than 50 participants per arm) or pilot studies. For an informal validation, we compared
the CoBalT MVN results (under MAR) with multiple imputation by chained equations using predictive mean‐matching
—which has been recommended to handle nonnormal data (White, Royston, & Wood, 2011)—and obtained very
similar results (see Data S4).
The estimation of the variance parameters in reference‐based approaches has been a source of discussion (Ayele
et al., 2014; Gao et al., 2017; Lu, 2014; Seaman, White, & Leacy, 2014). In particular, the model used for the imputation
step differs from the one used for the analysis, an issue referred to as “incongeniality.” Although the definition of what
should be the appropriate variance estimator when making assumptions about unobserved data is still an area for
debate, a recent study showed that the use of Rubin's rules with reference‐based multiple imputation has a desirable
“information‐anchored” property, in the sense that the amount of information lost by the missing data under MNAR
is similar to the information loss caused by the missing data under MAR (Cro, Carpenter, & Kenward, 2019). It is worth
TABLE 4 Summary of cost‐effectiveness results under different missing data assumptions
Missing
data
assumption
Difference in QALYs Difference in costs (£) ICER
(£/QALY)
Probability
cost‐
effectivea
Mean [95% CI] Mean [95% CI]
MAR 0.088 [0.035, 0.142] 996 [802, 1,190] 11,260 90.8%
J2Rb 0.079 [0.025, 0.134] 813 [630, 996] 10,244 90.8%
J2R interimc 0.078 [0.024, 0.132] 813 [630, 996] 10,423 90.0%
J2R‐MARd 0.079 [0.025, 0.134] 997 [801, 1,192] 12,552 84.4%
BMCFe 0.083 [0.029, 0.137] 996 [802, 1,190] 12,016 87.2%
Note. Based on N = 469 participants and m = 100 imputations. Note that results on the 368 participants with complete cost and effectiveness data were incre-
mental QALYs = 0.091 (95% CI [0.032, 0.149]) and incremental costs = £1,011 (95% CI [817, 1,204]).
Abbreviations: BMCF, baseline mean carried forward; CBT, cognitive behavioural therapy; CI, confidence interval; ICER, incremental cost‐effectiveness ratio;
J2R, jump to reference; M, mean; MAR, missing at random; QoL, quality of life; QALYs, quality‐adjusted life‐years.
aAt £20,000/QALY.
bAssuming QoL and costs for dropout participants in CBT arm jump to usual care values. Interim‐missing QoL assumed to be MAR.
cAssuming QoL and costs for dropout participants in CBT arm jump to usual care values, but interim‐missing QoL were assumed J2R.
dAssuming QoL and costs for dropout participants in CBT arm jump to usual care values, but missing costs were assumed MAR.
eAssuming QoL for dropout participants goes back to baseline values. Missing costs and interim‐missing QoL were assumed MAR.
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noting that although multiple imputation provides a particularly convenient framework for implementation, the prin-
ciples of reference‐based analysis are not necessarily tied with those of multiple imputation, and alternative frameworks
have been proposed (Lu, 2014).
One key challenge of MNAR sensitivity analyses concerns the choice of plausible missing data assumptions in
practice (Faria et al., 2014; Leurent, Gomes, Faria, et al., 2018). Although such assumptions are made more transparent
in the proposed method, these still need to be informed by subject‐matter knowledge and discussion with relevant
“experts” (e.g., trial investigators and practitioners, clinical experts, and patient representatives). The plausibility of each
assumption is likely to be a matter of debate, but it is important to keep in mind that the true missing data mechanism is
always unknown and that the aim of the sensitivity analyses is to indicate how results could differ under a range of
plausible assumptions (Morris, Kahan, & White, 2014). Ideally, the choice and plausibility of each assumption should
be prespecified, for example, in the health economic analysis plan (Dritsaki et al., 2018). If sensitivity analyses results
differ importantly, investigators should draw conclusions in light of the different results and the plausibility of the
respective assumptions (Leurent, Gomes, & Carpenter, 2018). An additional complexity in CEA is to formulate relevant
assumptions for each endpoint in light of their differential nature. For example, the J2R assumption is generally seen as
conservative for the effectiveness, as it assumes no treatment effect in those with missing data. This may not be the case
for the cost endpoint as the difference is typically expected in the opposite direction (new treatment more expensive)
and a J2R assumption then becomes liberal.
Although our case study clearly illustrates the principles of the reference‐based approach, it is not without limita-
tions. For example, we worked with a limited number of variables for clarity, but additional variables, such as individual
costs components could be included in the model. In addition, although the proportion of missing data was relatively
modest in our study, it would be interesting to investigate the extent to which larger amount of missing data may
amplify the impact of sensitivity analysis. The choice of MNAR assumption will be specific to each trial, and further
examples of applications in different settings would also be of interest.
The reference‐based approach is particularly appealing due to its qualitative formulation of the MNAR
assumptions, but it may not be the most appropriate approach to conduct sensitivity analysis in every trial‐based
CEA. In particular, other methods have been proposed based on a “delta” parameter, capturing the plausible
difference between observed and missing data (Faria et al., 2014; Leurent, Gomes, Faria, et al., 2018). This idea
is relatively flexible and may be an interesting alternative when none of the reference‐based option appear contextually
plausible. A fully Bayesian model has also been proposed to simultaneously handle missing data and complex
data structures, particularly when external data are available (e.g., expert beliefs) to inform priors (Baio, 2014;
Gabrio et al., 2018, 2019; Mason et al., 2018). Other references provide a more comprehensive review of alternative miss-
ing data methods (Molenberghs, Fitzmaurice, Kenward, Tsiatis, & Verbeke, 2014; Molenberghs & Kenward, 2007).
Reference‐based methods are still relatively novel, and there is scope for further research. Although the normality
assumption has been found reasonable for multiple imputation under MAR, assessing the robustness of the proposed
approach to nonnormal data in realistic settings is warranted. The approach could in theory be extended to
nonnormal models, and this would be an interesting area for further development. This paper considered scenarios
where one endpoint was assumed to be MAR and the other MNAR but did not allow for distinct MNAR mechanisms
simultaneously (e.g., assuming the effectiveness follows J2R and the cost LMCF). Another development would be to
allow for different mechanisms for different components of the endpoint. For example, assuming that self‐reported
resource use items are MNAR, whereas other costs items based on medical records are MAR. Finally, this paper
focused on addressing continuous outcomes, as these are most common in CEA (Leurent, Gomes, & Carpenter,
2018), but extending to other types of effectiveness measure (e.g., binary or time‐to‐event) would provide a valuable
contribution.
In conclusion, this study directly addresses the lack of accessible methods for handling MNAR data in trial‐based
CEA. Reference‐based multiple imputation is relatively straightforward to implement and facilitates the formulation
of relevant, accessible assumptions. We hope this approach will help future CEA based on incomplete trial data to
routinely conduct sensitivity analyses departing from the MAR assumption.
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